Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced Non-Small cell lung cancer following Platinum-Based doublet chemotherapy and immunotherapy (CANOPY-2): A Multicenter, Randomized, Double-Blind, phase 3 trial

•Patients with non-small cell lung cancer (NSCLC) have limited treatment options.•Canakinumab is approved for some autoinflammatory conditions.•Canakinumab previously reduced incidence and mortality of lung cancer (CANTOS study)•Canakinumab + docetaxel did not significantly improve survival in second-line NSCLC.•Survival was higher for some patient subgroups regardless of treatment.